Advertisement
Screener

CRONOS GROUP INC. (CRON) Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted

2.2 / 5 stars · 30/68 Roast Me

CRONOS GROUP INC. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted

CRONOS GROUP INC. (CRON) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of $32.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Other Income

us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2026-08-06

  • CRONOS GROUP INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-06-30 was $32.09M.
  • CRONOS GROUP INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-03-31 was $13.75M, a 124.63% increase year-over-year.
  • CRONOS GROUP INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-12-31 was -$1.82M, a 104.15% decline year-over-year.
  • CRONOS GROUP INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-09-30 was $25.96M, a 210.91% increase year-over-year.
  • CRONOS GROUP INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2025 was -$9.45M, a 123.00% decline from fiscal 2024.
  • CRONOS GROUP INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2024 was $41.08M.
  • CRONOS GROUP INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2023 was -$69.85M.
  • CRONOS GROUP INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2022 was -$155.18M.
Period endNet Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 monthNet Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month as first filedNet Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 monthNet Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month as first filedNet Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 monthNet Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 monthNet Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month as first filed
2026-06-30$32.09M
10-Q · filed 2026-08-06
$45.84M
10-Q · filed 2026-08-06
$44.02M
derived: sum of 3 quarters · filed 2026-08-06
$69.98M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$13.75M
10-Q · filed 2026-05-11
$11.94M
derived: sum of 2 quarters · filed 2026-05-11
$37.89M
derived: sum of 3 quarters · filed 2026-05-11
-$1.82M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$1.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$24.14M
derived: sum of 2 quarters · filed 2026-02-26
-$15.57M
derived: sum of 3 quarters · filed 2026-08-06
-$9.45M
10-K · filed 2026-02-26
2025-09-30$25.96M
10-Q · filed 2025-11-06
-$13.75M
derived: sum of 2 quarters · filed 2026-08-06
-$7.63M
10-Q · filed 2025-11-06
$36.10M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$39.71M
10-Q · filed 2026-08-06
-$33.59M
10-Q · filed 2026-08-06
$10.14M
derived: sum of 3 quarters · filed 2026-08-06
$18.49M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$6.12M
10-Q · filed 2026-05-11
$49.85M
derived: sum of 2 quarters · filed 2026-05-11
$58.20M
derived: sum of 3 quarters · filed 2026-05-11
$49.44M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31$43.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$52.08M
derived: sum of 2 quarters · filed 2026-02-26
$43.32M
derived: sum of 3 quarters · filed 2026-02-26
$41.08M
10-K · filed 2026-02-26
2024-09-30$8.35M
10-Q · filed 2025-11-06
-$408.00K
derived: sum of 2 quarters · filed 2025-11-06
-$2.65M
10-Q · filed 2025-11-06
-$47.56M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$8.76M
10-Q · filed 2025-08-07
-$11.00M
10-Q · filed 2025-08-07
-$55.91M
derived: sum of 3 quarters · filed 2026-02-26
-$57.37M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$2.24M
10-Q · filed 2025-05-08
-$47.16M
derived: sum of 2 quarters · filed 2026-02-26
-$48.62M
derived: sum of 3 quarters · filed 2026-02-26
2023-12-31-$44.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$46.38M
derived: sum of 2 quarters · filed 2026-02-26
-$69.85M
10-K · filed 2026-02-26
2023-09-30-$1.46M
10-Q · filed 2024-11-12
-$24.93M
10-Q · filed 2024-11-12
2022-12-31-$65.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$102.32M
derived: sum of 2 quarters · filed 2025-02-27
-$155.18M
10-K · filed 2025-02-27
-$168.73M
10-K · filed 2023-02-28
2022-09-30-$36.99M
10-Q · filed 2022-11-07
-$89.85M
10-Q · filed 2022-11-07
2021-12-31-$133.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$55.80M
derived: sum of 2 quarters · filed 2023-02-28
-$234.32M
derived: sum of 3 quarters · filed 2023-02-28
-$395.61M
10-K · filed 2023-02-28
2021-09-30$77.83M
10-Q · filed 2022-11-07
-$100.68M
derived: sum of 2 quarters · filed 2022-11-07
-$261.97M
10-Q · filed 2022-11-07
-$371.69M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$178.51M
10-Q/A · filed 2022-02-18
$57.62M
10-Q · filed 2021-08-06
-$339.80M
10-Q/A · filed 2022-02-18
-$103.68M
10-Q · filed 2021-08-06
-$449.52M
derived: sum of 3 quarters · filed 2023-02-28
-$380.70M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$161.31M
10-Q · filed 2021-05-07
-$271.01M
derived: sum of 2 quarters · filed 2023-02-28
-$202.19M
derived: sum of 3 quarters · filed 2023-02-28
-$309.85M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31-$109.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$40.88M
derived: sum of 2 quarters · filed 2023-02-28
-$148.54M
derived: sum of 3 quarters · filed 2023-02-28
-$72.49M
10-K · filed 2023-02-28
2020-09-30$68.82M
10-Q · filed 2022-02-18
$68.83M
10-Q · filed 2020-11-05
-$38.84M
derived: sum of 2 quarters · filed 2022-02-18
$37.21M
10-Q · filed 2022-02-18
$873.88M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$107.66M
10-Q/A · filed 2022-02-18
-$107.71M
10-Q · filed 2020-08-06
-$31.62M
10-Q/A · filed 2022-02-18
-$31.67M
10-Q · filed 2020-08-06
$805.07M
derived: sum of 3 quarters · filed 2022-03-01
$1.40B
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$76.04M
10-Q · filed 2021-05-07
$912.73M
derived: sum of 2 quarters · filed 2022-03-01
$1.51B
derived: sum of 3 quarters · filed 2022-03-01
$1.57B
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$836.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$1.43B
derived: sum of 2 quarters · filed 2022-03-01
$1.49B
derived: sum of 3 quarters · filed 2022-03-01
$1.14B
10-K · filed 2022-03-01
$1.14B
10-K/A · filed 2020-03-30
2019-09-30$597.49M
10-Q · filed 2020-11-05
$657.46M
derived: sum of 2 quarters · filed 2020-11-05
$305.76M
10-Q · filed 2020-11-05
2019-06-30$59.97M
10-Q · filed 2020-08-06
$149.33M
10-Q · filed 2020-08-06
2019-03-31$89.37M
10-Q · filed 2020-05-08
2018-12-31-$20.74M
10-K · filed 2021-02-26
-$21.64M
10-K/A · filed 2020-03-30
2017-12-31-$1.48M
10-K/A · filed 2020-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B
Definium Therapeutics, Inc. (DFTX)United States$4.931B-17.87